Search research articles
Contact Us
Filters
Showing results (971-980 of 1,171) with videos related to
Page
of 118
Sort By:
Nature Communications
|
May 4, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
Xin Cheng, Yadong Zhang, Changli Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
Leena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.
The New England Journal of Medicine
|
November 20, 2013
Stenting and medical therapy for atherosclerotic renal-artery stenosis
Christopher J Cooper, Timothy P Murphy, Donald E Cutlip, et al.
Cancer Cell
|
May 30, 2006
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
Hongbin Ji, Danan Li, Liang Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
British Journal of Cancer
|
November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
Giuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2016
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
Nicole G Chau, Yvonne Y Li, Vickie Y Jo, et al.
Molecular Cancer Therapeutics
|
December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Melissa L Johnson, Beni B Wolf, Judy S Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Sara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Page
of 118
Search research articles
Search
Showing results (971-980 of 1,171) with videos related to
Sort By:
Page
of 118
Nature Communications
|
May 4, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
Xin Cheng, Yadong Zhang, Changli Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
Leena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.
The New England Journal of Medicine
|
November 20, 2013
Stenting and medical therapy for atherosclerotic renal-artery stenosis
Christopher J Cooper, Timothy P Murphy, Donald E Cutlip, et al.
Cancer Cell
|
May 30, 2006
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
Hongbin Ji, Danan Li, Liang Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
British Journal of Cancer
|
November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
Giuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2016
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
Nicole G Chau, Yvonne Y Li, Vickie Y Jo, et al.
Molecular Cancer Therapeutics
|
December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Melissa L Johnson, Beni B Wolf, Judy S Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Sara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Page
of 118